InvestorsHub Logo
Followers 260
Posts 19732
Boards Moderated 0
Alias Born 10/03/2004

Re: JG36 post# 65820

Friday, 02/22/2013 2:46:49 PM

Friday, February 22, 2013 2:46:49 PM

Post# of 146288
Something happened between 2007 and the present, something outside management's control. First pharmaceuticals took a hit and what had been open season acquisition going into 2007 turned into a vacuum of deals by 2009. Funding and funds available dried up. No one funded anything for a year straight. When funding began to trickle in again it went to the politically and economically well-connected. Almost no progress was seen in the biopharma sector for 18 months from 2008 to mid-2009.

Something that management did have control over, but were a bit green and naive, was funding arrangements and the prospect of a partnership. In 2007, NNVC requested a $5 million defense bill earmark but was authorized $2 million in the final version passed by both the house and the senate. In a separate funding bill from the house, the bill that actually distributes budget items, in transposing the earmark's budget identification number, a zero was dropped from the item release, a number that must match exactly as the authorization is an act of law. The budget item $2 million could not be released. There were more in the series of unfortunate events, but to me these two alone account for almost 3 years of delay from the original projection.

So, there is much more to this story than a product pipeline, there are the politics, the industrial intrigue, the threat to current therapies from disruptive technology, among other things.

"It ain't what they call you, it's what
you answer to." --WC Fields

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NNVC News